ValiRx plc (GB:VAL) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ValiRx’s subsidiary, Inaphaea BioLabs, has successfully shipped its first batch of Assay Ready Reagents, marking a significant step in the company’s commercialization efforts. These reagents, derived from a biobank of over 450 patient-derived cells, offer a new revenue stream by allowing customers to conduct assays without in-house cell growth. This milestone highlights ValiRx’s strategic advancement in providing innovative cancer therapeutics and women’s health solutions.
For further insights into GB:VAL stock, check out TipRanks’ Stock Analysis page.
